Skip to main navigation Skip to search Skip to main content

Reproducibility study of the pharmacokinetics of amikacin, gentamicin and tobramycin; a three-way crossover study

  • A. Dyas
  • , R. Wise*
  • , J. Pijck
  • , Th Hallynck
  • , J. Acar
  • , D. Adam
  • , R. Cadorniga
  • , M. Wenk
  • , H. H. Soep
  • *Corresponding author for this work
  • Sandwell and West Birmingham Hospitals NHS Trust
  • Farmaceutisch Institut
  • Hôpital Saint-Joseph
  • Ludwig Maximilian University of Munich
  • Complutense University
  • Kantonspital
  • Bristol Myers Company

Research output: Contribution to journalArticlepeer-review

Abstract

The hypothesis that the pharmacokinetics of amikacin are more predictable than those of gentamicin or tobramycin was studied.In a three-way crossover design 58 volunteers received 7.5 mg/kg amikacin by iv infusion and either 1.5 mg/kg or 1 mg/kg gentamicin and tobramycin. The mean half-life and mean serum concentration at 1 h for each drug was determined. No consistent significant difference was found between the pharmacokinetics of amikacin and the other two drugs.

Original languageEnglish
Pages (from-to)371-376
Number of pages6
JournalJournal of Antimicrobial Chemotherapy
Volume12
Issue number4
DOIs
Publication statusPublished - Oct 1983
Externally publishedYes

Fingerprint

Dive into the research topics of 'Reproducibility study of the pharmacokinetics of amikacin, gentamicin and tobramycin; a three-way crossover study'. Together they form a unique fingerprint.

Cite this